Emendo Biotherapeutics is pioneering advancements in CRISPR technology to address complex genetic diseases through a tailored approach. Recognizing the limitations of the original CRISPR-Cas9 system, the company has developed a platform that focuses on understanding the specific characteristics of each genetic disease before designing an optimal gene editing strategy. This involves creating customized nucleases and guide RNAs that are specifically optimized for the unique challenges posed by different genetic conditions, thereby enhancing the precision and efficacy of gene editing.

The company's innovative approach aims to eliminate off-target effects, which are a common concern in traditional CRISPR applications. By prioritizing a disease-first methodology, Emendo Biotherapeutics ensures that their gene editing solutions are not only effective but also safe for therapeutic use. This commitment to customizing their technology for each genetic disease underscores their belief that every genetic medicine should be as unique as the disease it aims to treat, ultimately striving to unlock the full potential of CRISPR for improving human health.

United States

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.  

We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

Emendo Biotherapeutics

Company Details